Lotus Eye Hospital And Institute Ltd AI Stock Analysis
Want to see IN:LOTUSEYE full AI Analyst Report?
Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis
Lotus Eye Hospital And Institute Ltd
(NSE:LOTUSEYE)
The score is primarily held back by weak financial performance—sharp margin deterioration, rising leverage, and deeply negative free cash flow—despite continued revenue growth. Technicals are broadly neutral with negative MACD and the price below key longer-term moving averages. Valuation is a major headwind due to an extremely high P/E and no dividend yield provided.
Lotus Eye Hospital And Institute Ltd (LOTUSEYE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 2.12B
- Dividend Yield
- ―
- Average Volume (3M)
- 2,286
- Price to Earnings (P/E)
- 444.6
- Beta (1Y)
- 0.57
- Revenue Growth
- 23.11%
- EPS Growth
- -29.81%
- Country
- India
- Employees
- 402
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model
Company Description
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik e...
Lotus Eye Hospital And Institute Ltd Financial Statement Overview
Summary
Revenue continues to grow (FY2026 up ~6.8% YoY), but profitability weakened sharply: net margin fell to ~0.15% and operating margin turned slightly negative (~-0.7%). Balance sheet leverage rose quickly (debt-to-equity ~0.26 vs ~0.06 prior year) and free cash flow swung deeply negative (~-106M), increasing funding and execution risk.
Income Statement
44NeutralBalance Sheet
58NeutralCash Flow
28Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 572.54M | 537.14M | 495.63M | 482.10M | 470.44M | 389.10M |
| Gross Profit | 145.80M | 102.25M | 100.41M | 135.66M | 121.38M | 192.53M |
| EBITDA | 55.97M | 45.55M | 47.44M | 79.42M | 88.37M | 68.09M |
| Net Income | 1.49M | 804.00K | 7.39M | 29.14M | 40.77M | 29.84M |
Balance Sheet | ||||||
| Total Assets | 0 | 825.97M | 695.74M | 666.27M | 631.88M | 615.97M |
| Cash, Cash Equivalents and Short-Term Investments | 38.27M | 37.26M | 39.78M | 69.30M | 83.31M | 87.93M |
| Total Debt | 0 | 158.34M | 34.30M | 11.10M | 11.04M | 12.38M |
| Total Liabilities | -601.38M | 224.60M | 95.73M | 72.17M | 56.09M | 69.88M |
| Stockholders Equity | 601.38M | 601.38M | 600.00M | 594.09M | 575.79M | 546.09M |
Cash Flow | ||||||
| Free Cash Flow | -2.68M | -106.28M | -21.25M | 403.00K | 12.90M | -2.73M |
| Operating Cash Flow | 5.09M | 24.15M | 27.02M | 56.83M | 43.87M | 44.12M |
| Investing Cash Flow | -4.83M | -125.78M | -43.50M | -46.33M | -21.94M | -39.35M |
| Financing Cash Flow | -9.27M | 98.39M | -12.42M | -34.02M | -17.05M | -15.75M |
Lotus Eye Hospital And Institute Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Negative. The current price of 103.65 is below the 20-day moving average (MA) of 106.82, below the 50-day MA of 110.39, and below the 200-day MA of 114.67, indicating a bearish trend. The MACD of -2.15 indicates Positive momentum. The RSI at 43.79 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LOTUSEYE.
Lotus Eye Hospital And Institute Ltd Peers Comparison
Overall Rating
IN:MEDANTA69Neutral
IN:MAXHEALTH63Neutral
IN:APOLLOHOSP62Neutral
IN:FORTIS61Neutral
IN:ASTERDM55Neutral
IN:LOTUSEYE43.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | INR 397.40B | 64.22 | ― | 0.07% | 26.18% | 10.09% | |
| 63Neutral | INR 1.01T | 73.39 | ― | 0.19% | 15.17% | 1.63% | |
| 62Neutral | INR 1.26T | 56.03 | ― | 0.23% | 19.24% | 34.11% | |
| 61Neutral | INR 610.61B | 58.85 | ― | 0.12% | 17.50% | 2.40% | |
| 55Neutral | INR 644.56B | 102.25 | ― | 0.54% | 50.47% | 10.73% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | INR 2.16B | 444.56 | ― | ― | 23.11% | -29.81% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:LOTUSEYE | Lotus Eye Hospital And Institute Ltd | 103.65 | -1.20 | -1.14% | |
| IN:APOLLOHOSP | Apollo Hospitals Enterprise Limited | 8744.80 | 1370.25 | 18.58% | |
| IN:ASTERDM | Aster DM Healthcare Ltd. | 739.45 | 89.55 | 13.78% | |
| IN:FORTIS | Fortis Healthcare Ltd. | 808.80 | -111.27 | -12.09% | |
| IN:MAXHEALTH | Max Healthcare Institute Ltd | 1038.30 | -140.36 | -11.91% | |
| IN:MEDANTA | Global Health Limited | 1478.00 | 252.09 | 20.56% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 12, 2026
